The long-term survival of patients with glioblastoma is compromised by the proclivity for local invasion into the surrounding normal brain, escaping surgical resection and contributing to therapeutic resistance. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK), a member of the tumor necrosis factor superfamily, can stimulate glioma cell invasion via binding to fibroblast growth factor-inducible 14 (Fn14) and subsequent activation of the Rho guanosine triphosphatase family member Rac1. Here, we demonstrate that TWEAK acts as a chemotactic factor for glioma cells, a potential process for driving cell invasion into the surrounding brain tissue. TWEAK exposure induced the activation of Src family kinases (SFKs), and pharmacologic suppression of SFK activity inhibited TWEAK-induced chemotactic migration. We employed a multiplexed Luminex assay and identified Lyn as a candidate SFK activated by TWEAK. Depletion of Lyn suppressed TWEAK-induced chemotaxis and Rac1 activity. Furthermore, Lyn gene expression levels increase with primary glioma tumor grade and inversely correlate with patient survival. These results show that TWEAK-induced glioma cell chemotaxis is dependent upon Lyn kinase function and, thus, provides opportunities for therapeutic targeting of this deadly disease.
Introduction
Glioblastoma (GB) is the most common and lethal primary malignant brain tumor, affecting 25 000 patients per year (1) . Despite major research efforts and advances in diagnosis and treatment, the overall survival of patients has improved little over the last 30 years and remains at a mean of 14.6 months (2). One aspect of glioma biology that contributes to its poor prognosis is diffuse infiltration of glioma cells (3) . Invasion of normal brain by infiltrating tumor cells makes complete surgical removal of the tumor challenging and underlies therapeutic failures (4) . To date, the underlying mechanisms of invasion are not well understood and no specific treatment has been developed targeting this lethal tumor cell phenotype (5) (6) (7) .
The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) signaling pathway has been implicated in cancer biology and Fn14 is overexpressed in many solid tumor types (8, 9) . Our lab has reported elevated Fn14 expression in advanced brain cancer samples, correlating with poor patient outcome (10, 11) . TWEAK activation of Fn14 induces glioma cell migration and invasion through Rac1 and NF-κB signaling pathways (11) . Additionally, TWEAK stimulates glioma cell survival through NF-κB activation and upregulation of prosurvival genes including BCL-xL, BCL-W and AKT2 (12, 13) . TWEAK is expressed at relatively low levels in GB samples as compared with normal brain (10) . In fact, TWEAK is expressed by microglia cells and astrocytes in normal brain (14) , and an earlier report demonstrated that microglia cells and microglia-conditioned medium increased GB cell migration, supporting and promoting the invasive phenotype of glioma cells (15) . Thus, TWEAK produced in the brain parenchyma may bind to Fn14 on the glioma cell surface and contribute to glioma cell invasiveness. In this context, the TWEAK/Fn14 pathway may represent a potential therapeutic vulnerability of the invasive phenotype.
The Src family kinases (SFKs) have long been known to contribute to tumor progression by regulating apoptosis, proliferation, cell adhesion, cell migration, cell invasion, angiogenesis and metastasis (reviewed in ref. 16, 17) . Of the nine SFK members, only five (Src, Lyn, Fyn, Lck and Yes) were reported to be expressed in neuronal tissue (18) . Active SFKs were detected in 60% of primary GB by bead-based profiling or immunohistochemistry, and the Src inhibitor dasatinib inhibited glioma viability and invasion both in vitro and in vivo (19) . Lyn tyrosine kinase has been implicated in maintaining the leukemic phenotype of many liquid cancers and also known to be overexpressed in many solid tumor types including GB (20) . It was also reported that Lyn kinase activity might account for the majority of SFK activity in GB tumor samples (21) . Lyn depletion inhibited glioma cell migration driven by platelet-derived growth factor (22) . Other SFK members have been associated with glioma invasion, including Yes in association with CD95 (23) , and Fyn and Src associated with mutant epidermal growth factor receptor (24) . Thus, individual SFK members may play a role in the propensity for glioma cell invasion into brain parenchyma.
In this report, we demonstrate that TWEAK induces chemotactic migration of glioma cells. We further show that TWEAK stimulates SFK phosphorylation in glioma cells and that inhibition of SFK activity inhibits glioma cell migration. We identified that a specific SFK member, Lyn, functions downstream of TWEAK/ Fn14 signaling axis and depletion of Lyn is sufficient to abrogate TWEAK-induced Rac1 activation and subsequently, glioma cell chemotactic migration. Importantly, we show that Lyn expression correlates with advancing tumor grade in primary brain tumors and correlates with shorter patient survival. Overall, our results demonstrate that TWEAK-induced Lyn activation may be an important signaling mechanism that promotes the invasion of glioma cells into the surrounding brain parenchyma, a phenotype responsible for poor prognosis.
Materials and methods

Cell culture conditions
Human GB cell lines T98G and A172 (American Type Culture Collection, Manassas, VA) were maintained in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Carlsbad, CA) supplemented with 10% heatinactivated fetal bovine serum (Life Technologies) at 37°C with 5% CO 2 atmosphere at constant humidity. In all TWEAK addition experiments, the cells were cultured in reduced serum (0.5% fetal bovine serum) for 16 h before stimulation with recombinant TWEAK at 100 ng/ml in DMEM + 0.1% bovine serum albumin (BSA).
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pan phospho-Src and phospho-tyrosine were purchased from Cell Signaling Technology (Danvers, MA).
Migration assay
Chemotaxis of T98G and A172 cells in response to TWEAK was analyzed by use of modified Boyden chamber migration assays as described previously (25, 26) . TWEAK was added to the lower wells of a 12-well modified Boyden chamber (Neuroprobe, Cabin John, MD) using DMEM with 0.1% BSA as assay medium. Wells were covered with an 8 µm pore size Nucleopore filter (Neuroprobe) that had been coated with 50 µg/ml PureCol® (Bovine Collagen; Advanced Biomatrix, Poway, CA). GB cells were suspended at 4.8 × 10
4 cells in 100 µl of assay medium and seeded into the upper wells. After incubation for 5 h at 37°C, non-migrated cells were scraped off the upper side of the filter, and filters were stained with 4′,6-diamidino-2-phenylindole. Nuclei of migrated cells were counted in five high power fields with a ×20 objective. Values were assessed in triplicate. For checkerboard analyses, TWEAK was added to either the upper or the lower wells, or both, at the concentrations indicated in the Results. For Fn14-Fc DcR analyses, TWEAK and DcR were added together in bottom well at the concentrations as indicated in the Results. For analyzing the pharmacological inhibition of SFK phosphorylation on TWEAK-induced chemotactic migration, GB cells were treated with PP2 for 1 h prior to the start of migration assay in tissue culture dish and also added on top well in the modified Boyden chamber at the concentrations indicated in the Results.
Western blot analysis
Western blotting was conducted as described previously (12) . Briefly, monolayers of cells were washed in phosphate-buffered saline containing 1 mM phenylmethylsulfonyl fluoride and 1 mM sodium orthovanadate and then lysed in 2× sodium dodecyl sulfate (SDS) sample buffer (0.25 mol/l Tris-HCl, pH 6.8, 10% SDS, 25% glycerol) containing 10 mg/ml aprotinin, 10 mg/ml leupeptin, 20 mmol/l NaF, 2 mmol/l sodium orthovanadate and 1 mmol/l phenylmethylsulfonylfluoride. Protein concentrations were determined using the bicinchoninic acid assay (Pierce) with BSA as a standard. Thirty micrograms of total cellular protein was loaded per lane and separated by SDS-polyacrylamide gel electrophoresis. After transfer at 4°C, the nitrocellulose membrane (Invitrogen) was blocked with either 5% non-fat milk or 5% BSA in Trisbuffered saline, pH 8.0, containing 0.1% Tween-20 before addition of primary antibodies and followed with peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG. Protein bands were detected using Super Signal West Dura Chemiluminescent Substrate (Pierce) with a UVP BioSpectrum 500 Imaging System.
Luminex assay
MILLIPLEX MAP 8-Plex Human Src Family Kinase Phosphoprotein Kit (27) and GAPDH MAPmate kit were purchased from Millipore and used according to manufacturer's instructions. GAPDH MAPmate kit was implemented as loading control and mixed with 8-Plex Human SFK kit. Briefly, cell lysates were collected using lysis buffer supplied with the kit and protein concentrations were determined as described above. Protein concentrations were adjusted to 1 mg/ml using MILLIPLEX MAP Assay Buffer 2. Next, 25 µl of each protein lysate was added with a mixture of 1× 9-plex bead set [8-Plex SFK bead set + glyceraldehyde 3-phosphate dehydrogenase (GAPDH) beads] per well of 96-well plate and incubated overnight at 4°C on slow shaker. Subsequently, 25 µl of 1× biotinylated antibody mixture was added to each well containing 9-plex bead set with captured proteins and incubated for 1 h at room temperature with slow shaking in dark. Next, 25 µl of 1× streptavidin-phycoerythrin solution was added to each well and incubated for 15 min at room temperature. Subsequently, 25 µl of amplification buffer was added to each well and incubated for 15 min at room temperature. Finally, 9-plex bead set with captured proteins, their respective biotinylated antibodies, and streptavidin-phycoerythrin were resuspended in 150 µl of assay buffer and read on Luminex 200™ χMAP analyzer. Median fluorescent intensities (MFI) for triplicate wells were averaged. MFI readouts comparing the activation state of each of the eight SFKs consequent to TWEAK stimulation (as normalized to average MFI of loading control, GAPDH beads) were analyzed using a two-way analysis of variance. Statistical significance was assigned if P <0.05 as compared with baseline activation of each of eight SFKs.
Immunoprecipitation and Rac1 activity assay
Immunoprecipitation was performed as described previously (28) . Briefly, cells were lysed on ice for 10 min in a buffer containing 10 mmol/l Tris-HCl (pH 7.4), 0.5% Nonidet P-40, 150 mmol/l NaCl, 1 mmol/l phenylmethylsulfonylfluoride, 1 mmol/l ethylenediaminetetraacetic acid, 2 mmol/l sodium orthovanadate, 10 mg/ml aprotinin and 10 mg/ml leupeptin (Sigma). Equivalent amounts of protein (500 mg) were precleared and immunoprecipitated from the lysates and then washed with lysis buffer followed by S1 buffer [10 mmol/l N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (pH 7.4), 0.15 mol/l NaCl, 2 mmol/l ethylenediaminetetraacetic acid, 1.5% Triton X-100, 0.5% deoxycholate and 0.2% SDS]. Samples were then resuspended in 2× SDS sample buffer and boiled in the presence of 2-mercaptoethanol (Sigma), separated by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose for 1 h at 4°C, and proteins were detected using SuperSignal West Dura Chemiluminescent Substrate (Pierce). Rac1 activity assays were performed according to the manufacturer's protocol (Pierce). Lysates were harvested after luciferase control or Lyn small interfering RNA (siRNA) treatment, and equal amounts of lysates were assessed for Rac1 activity.
siRNA preparation and transfection siRNA oligonucleotide specific for GL2 luciferase (29) was designed, validated and purchased from Qiagen (Valencia, CA). siRNA oligonucleotide for Lyn was designed, validated and purchased from IDT (Coralville, IA): Lyn (5′-UCCUGAAAUAGAGGCUAAAUUACTC-3′). Cells were plated in a 60 mm plate at 2.5 × 10 5 cells per plate in 3 ml of DMEM, supplemented with 10% serum without antibiotics. After cells were fully adherent, transfections with Lyn siRNA oligonucleotides or control GL2 luciferase siRNA oligonucleotides were carried out using RNAiMAX (Life Technologies) according to the manufacturer's protocol (20 nM GL2 luciferase and 5 nM Lyn for 16 h). Cells were assayed on day 3 (72 h) after transfection. No cell toxicity was observed using this protocol.
Organotypic brain slice invasion assay
An ex vivo invasion assay into rat brain slices was done as described previously (11) . Briefly, 400 µm thick vital sections were prepared from brains of Wistar rats (Charles River Laboratories) floated on micropore membranes in culture media. Glioma cells (1 × 10 5 ; T98G and A172) stably expressing green fluorescence protein were first treated with Lyn siRNA or GL2 luciferase siRNA and then gently deposited (0.5 µl transfer volume) bilaterally onto the putamen of the rat brain slice. Deposited cells were then allowed to invade and observed after 48 h. Forty-eight hours after seeding the cells, glioma cell invasion into the rat brain slices was detected using a LSM 5 Pascal laser scanning confocal microscope (Zeiss) to observe green fluorescence protein-labeled cells in the tissue slice. Serial optical sections were obtained every 10 µm downward from the surface plane to the bottom of the slice, and for each focal plane, the area of fluorescent cells as a function of the distance from the top surface of the slice was calculated. The extent of glioma cell invasion was reported as the depth where the area of fluorescent tumor cells was half of the maximum area at the surface.
Expression profile data set of SFKs in human gliomas and non-neoplastic brain
We mined an expression microarray database consisting of 502 clinically annotated brain tumor specimens publicly available at National Cancer Institute's Repository for Molecular Brain Neoplasia Data (REMBRANDT) for determining SFK family member messenger RNA (mRNA) expression levels. Snap-frozen specimens from epileptogenic foci (n = 28) and tumors (155 low-grade astrocytomas, 80 oligodendrogliomas and 239 GBs) with clinical information were collected at different sites. Gene expression profiling was conducted on all samples using Affymetrix U133 Plus 2 GeneChips according to the manufacturer's protocol at the Neuro-Oncology Branch at the National Cancer Institute as described previously (11) . For our analysis, gene expression data were normalized in two ways: per chip normalization and per gene normalization across all samples in the collection. For per chip normalization, all expression data on a chip were normalized to the 50th percentile of all values on that chip. For per gene normalization, the data for a given gene were normalized to the median expression level of that gene across all samples. Gene expression differences were deemed statistically significant using parametric tests where variances were not assumed equal (Welch analysis of variance). Expression values were then filtered for highly variable (differentially expressed) genes (coefficient of variation > 30%) across samples, producing a list of 7322 genes. Principal component analysis was done to discern possible relationships between subgroups of samples as described previously (11) , and Kaplan-Meier survival curves were developed for each principal component cluster. One cluster had a median survival time of 401 days (short-term survival) and the other cluster had a median survival time of 952 days (long-term survival). Box-and-whisker plots for all SFK expression levels in each cluster derived from principal component analysis were graphed. Significance between the two populations was tested with a twosample t-test assuming unequal variances. Coexpression analysis between Fn14 and selected SFKs (Lyn and Yes) was performed on 394 glial tumor specimens (155 low-grade astrocytomas and 239 GBs). Pearson correlation
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et al. test was applied to determine the correlation between expressions of Fn14 and Lyn/Yes.
Results
TWEAK induces chemotactic migration of glioma cells
We have previously demonstrated that the activation of Fn14 by its cognate ligand TWEAK stimulates glioma cell migration and invasion via Rac1 activation (10, 11, 28) . Here, we assessed if TWEAK functions as a chemotactic factor for glioma cells. Two Fn14-positive glioma cell lines, T98G and A172 ( Figure 1A) , were selected to assess the chemotactic effects of TWEAK. Modified checkerboard assay design was implemented to distinguish between chemotaxis (directed movement) and chemokinesis (random movement) (26, 30) . TWEAK addition resulted in a 2.0-and 2.5-fold increase in chemotactic migration in T98G and A172 cells, respectively, whereas chemokinetic migration was unaffected by TWEAK exposure ( Figure 1B) . To investigate whether TWEAK stimulation of chemotactic cell migration is dependent upon Fn14 activation, a soluble Fn14-Fc DcR was applied (11, 31) . Pretreatment with the Fn14-Fc DcR suppressed TWEAK-induced chemotactic migration in T98G and A172 cells ( Figure 1C) . These results suggest that TWEAK induces chemotactic migration of glioma cells via binding to the Fn14 receptor. Checkerboard analysis on T98G and A172 glioma cells was performed using modified Boyden chamber assay. Glioma cells were added to the top well and TWEAK was added either to the lower or to the upper well or to both wells at 100 ng/ml. Values are mean ± SD of triplicate measurements (*P < 0.05). (C) T98G and A172 glioma cells were added to the top well and either only TWEAK (100 ng/ml) or TWEAK and Fn14-Fc DcR (2.5 µg/ml) was added to the lower wells. Values are mean ± SD of triplicate measurements (*P < 0.05). HPF, high power field.
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TWEAK stimulation of chemotactic migration is modulated by SFKs
Since Fn14 is not a receptor tyrosine kinase (8, 32) , a promising candidate mediating chemotaxis signaling downstream of TWEAK-Fn14 interaction could be non-receptor tyrosine kinases, such as the SFKs. To investigate whether SFKs are activated upon TWEAK stimulation of glioma cells, we assessed phosphorylation of SFK on tyrosine 419 using a pan-Src antibody that recognizes six SFK members (Src, Lyn, Fyn, Lck, Yes and Hck) (33, 34) . TWEAK stimulation of A172 and T98G cells induced rapid phosphorylation of SFK (Figure 2A ), whereas TWEAK exposure had no effect on total SFK protein levels. To investigate whether inhibiting SFK phosphorylation blocks TWEAK stimulation of chemotactic cell migration, a selective inhibitor of SFK activity, PP2, was applied (16, 35) . Pretreatment of glioma cells with PP2 prior to TWEAK stimulation completely suppressed chemotactic migration for both T98G and A172 ( Figure 2B ). These results suggest that SFK activation mediates TWEAK-induced chemotactic migration of glioma cells.
Lyn depletion inhibits TWEAK-induced chemotactic migration
To determine the specific SFK family member that probably mediates TWEAK-induced chemotactic migration of glioma cells, we compared the activation status of eight different SFK members (Src, Lyn, Fyn, Lck, Yes, Hck, Blk and Fgr) upon TWEAK stimulation. Rapid phosphorylation of Lyn was detected upon TWEAK treatment in both T98G ( Figure 3A ) and A172 cells ( Figure 3B ). TWEAK exposure also significantly induced the phosphorylation of YES in both T98G and A172 cells and Src in A172 cells. Because Lyn activity was robustly induced in both cell lines after TWEAK exposure, our subsequent experiments focused on this particular SFK. We first confirmed Lyn phosphorylation upon TWEAK stimulation of T98G cells by immunoprecipitation assay (inset in Figure 3A) .
To validate the role of Lyn in mediating TWEAK-induced chemotactic migration, Lyn protein levels were depleted in T98G and A172 cells using Lyn-specific siRNA. Western blot analysis showed >90% decrease in Lyn protein levels in both cell lines transfected with Lyn siRNA as compared with luciferase control siRNA ( Figure 3C ). Depletion of Lyn completely abrogated TWEAK-induced chemotactic migration in both T98G and A172 cells ( Figure 3D ), whereas depletion of Src or Yes failed to inhibit TWEAK-induced chemotactic migration (data not shown). These data suggest that Lyn plays an important role in TWEAK-induced chemotactic migration in glioma.
Knockdown of Lyn expression suppresses TWEAK-induced Rac1 activation in vitro and glioma invasion ex vivo
Our lab has established that TWEAK-stimulated glioma cell migration and invasion is dependent on Rac1 activation (11). We, therefore, examined whether siRNA knockdown of Lyn suppresses Rac1 activation. Depletion of Lyn using siRNA oligonucleotide suppressed TWEAK-induced Rac1 activation ( Figure 4A ), thus suggesting that Lyn functions upstream of Rac1. In addition, siRNA-mediated depletion of Rac1 expression suppresses TWEAK-induced glioma cell chemotactic migration ( Figure 4B ). Thus, these data suggest that TWEAK stimulation of glioma cell chemotactic migration is dependent upon Lyn-Rac1 activation. We next investigated whether Lyn knockdown affects glioma cell invasion using an ex vivo rodent brain slice model, a well-established organotypic model (36) . We found that siRNA-mediated depletion of Lyn significantly impaired invasion of two glioma cell lines, T98G and A172, into the brain tissue ( Figure 4C) . These data further demonstrate the importance of Lyn in mediating glioma cell invasion. Figure S1 , available at Carcinogenesis Online). In contrast, SRC mRNA expression was relatively unchanged between NB specimens and glial tumors ( Figure 5A ).
Lyn mRNA expression levels correlate with brain tumor grade and poor patient outcome
Further, we applied principle component analysis on a subset of the REMBRANDT dataset (Henry Ford data set, National Center for Biotechnology Information Gene Expression Omnibus data set GSE4290) to query the relationship between the expression of each of the SFK and patient outcome as described previously (11, 13) . By principle component analysis, GB patients were segregated into two separate clusters displaying distinct Kaplan-Meier survival curves.
Cluster 1 has a median survival time of 952 days [long-term (LT)], whereas cluster 2 has a median survival of 401 days [short-term (ST)]. Analysis of the expression for each SFK showed that GB patients in the short-term survival cluster had significantly higher Lyn (P < 0.001) ( Figure 5B) and YES (P < 0.05) (Supplementary Figure S2 , available at Carcinogenesis Online) mRNA levels than GB patients in the long-term survival cluster. All other SFK expression levels were not significantly different between GB patients in the long-term survival cluster compared with GB patients in the short-term survival cluster ( Figure 5B; Supplementary Figure S2 , available at Carcinogenesis Online). These findings suggest that high Lyn expression levels correlate with increasing brain tumor grade and poor patient outcome. Subsequently, we also looked at the correlation between expression levels of 
Discussion
In this study, we demonstrated that TWEAK could act as a chemotactic factor for GB cells. In addition, we showed that TWEAK activates SFK activity and that suppression of SFK activity abrogated TWEAK-induced chemotaxis. We further elucidated that LYN activation occurred after TWEAK exposure while LYN depletion was Figure 3A shows immunoprecipitation analysis of T98G cells after TWEAK stimulation. T98G and cells were treated with TWEAK (100 ng/ml) for the indicated times, lysed and immunoprecipitated using Lyn specific antibody, and western blot analysis was performed using anti-pan phospho-tyrosine antibody and total Lyn antibody (loading control). siRNA knockdown of Lyn suppresses chemotactic migration of glioma cells in vitro. (C) T98G and A172 cells were transfected with either luciferase control siRNA or Lyn-specific siRNA, incubated for 72 h and lysed, and western blot analysis was performed using anti-Lyn antibody (α-tubulin used as a loading control). (D) Effect of siRNA knockdown of Lyn on TWEAK-induced chemotactic migration of T98G and A172 glioma cells was determined using modified Boyden chamber assay. Glioma cells transfected with luciferase control (Luc.) or Lyn siRNA were added to the top well and TWEAK (100 ng/ml) was added to the lower wells. Values are mean ± SD of triplicate measurements (*P < 0.05). HPF, high power field. sufficient to inhibit TWEAK-induced chemotactic migration through Rac1. Finally, we demonstrated that LYN mRNA expression in primary patient brain tumors correlated with advancing tumor grade, shortened patient survival and Fn14 mRNA expression.
The role of the TWEAK/Fn14 signaling axis in tumor cell migration and invasion has been well established across multiple solid tumor types (reviewed in ref. 8) . Our lab has demonstrated that TWEAK and Fn14 are associated with increased tumor cell migration and invasion in breast cancer, non-small-cell lung cancer and GB (10, 11, (37) (38) (39) . In glioma tumor cells, TWEAK/Fn14-driven cell migration was dependent on Rac1 activity and NF-κB signaling (11) . Here, we demonstrated that TWEAK could act as a chemotactic factor for GB cells. We further show that Rac1 is necessary for TWEAK-induced chemotactic migration of glioma cells. The critical role of active Rac1 in the orchestration of chemotactic cell movement is well established (40) . Tumor necrosis factor ligands have also been associated with chemotactic migration, especially in immune cell migration (41) . Donohue et al. (31) previously showed that TWEAK could act as a chemotactic factor stimulating endothelial cell migration. Thus, epithelial, endothelial and immune cells expressing Fn14 may respond to TWEAK with a migratory phenotype. As it has been shown that the TWEAK is expressed by astrocytes and microglia in central nervous system (14) , the presence of TWEAK in the brain parenchyma may help drive glioma tumor cell invasion. Inhibitors of the TWEAK/Fn14 pathway are an area of active therapeutic investigation and may prove to be a vulnerability to invasive glioma cells. Clinical trials with agents targeting the TWEAK/Fn14 axis are currently ongoing (42) . (A) T98G cell were transfected with either luciferase control siRNA or Lyn-specific siRNA, incubated for 72 h, treated with TWEAK (100 ng/ml) for 10 min and lysed, and Rac1 activity was determined using Rac1 activity assay kit. (B) Effect of siRNA knockdown of Rac1 on TWEAK-induced chemotactic migration of T98G and A172 glioma cells was assessed using modified Boyden chamber assay. Glioma cells transfected with luciferase control (Luc.) or Lyn-specific siRNA were added to the top well and TWEAK (100 ng/ml) was added to the lower wells. Values are mean ± SD of triplicate measurements (*P < 0.05). HPF, high power field. (C) siRNA knockdown of Lyn suppresses glioma cell invasion ex vivo. T98G and A172 glioma cells stably expressing green fluorescence protein were transfected with Lyn siRNA and implanted into the bilateral putamen on rat organotypic brain slices. Implanted cells were observed after 48 h, and depth of invasion was calculated from Z-axis images collected by confocal laser scanning microscopy. The mean value of the depth of invasion was obtained from four independent experiments (*P < 0.0001). GTP, guanosine triphosphate.
SFKs have been shown to be involved in regulation of variety of cellular processes including many of the hallmarks of cancer (43), i.e. cell adhesion, cell invasion, cell proliferation, cell survival and angiogenesis (16, 17, 33, 34) . These findings have led to the therapeutic targeting of SFKs for various cancers, which has shown some promises in the previous studies (16, 34) . SFKs are known to activate a variety of cytoskeletal proteins in responses to extracellular cues (33) and have been reported to play an important role in cancer cell invasion (16, 23, 44) . Here we demonstrated that TWEAK treatment of glioma cells induced phosphorylation of SFKs. The pharmacologic inhibition of SFK activity completely abrogated TWEAK-induced chemotactic migration. The mechanisms through which TWEAK/Fn14 activate SFKs is an area of current investigation. As Fn14 has been shown to interact with multiple TNFR-associated factor (TRAF) proteins (32) , and SFKs have been demonstrated to complex with TRAF proteins leading to kinase activation (45), the TRAF-binding cytoplasmic tail of Fn14 may be critical for SFK activation.
Despite the fact that Src is one of the oldest and most researched proto-oncogenes (46), specific signaling roles for individual SFKs in cancer are not well understood (16, 34) . Only five of the SFK members (Src, Lyn, Fyn, Lck and Yes) are reported to be expressed in neuronal tissue (reviewed in ref. 18 ). Stettner et al. (21) demonstrated a predominant role for Lyn kinase activity in glioma cells. Lyn kinase activity was significantly elevated in GB tumor samples and accounted for more than 90% of the pan-Src kinase activity, suggesting that Lyn activity may promote GB malignant phenotype. In this study, we showed that TWEAK:Fn14 engagement activates Lyn kinase and that depletion of Lyn was sufficient to inhibit TWEAK-induced chemotactic migration. Ding et al. (22) previously demonstrated that platelet-derived growth factor-driven glioma cell migration increased Lyn activity and Lyn depletion suppressed platelet-derived growth factor-induced migration, supporting a role for Lyn in the glioma invasive phenotype. Other SFK members have also been demonstrated to affect glioma cell migration. The SFK member Yes has been implicated in association with CD95 and PI3K to induce GB invasion (23) . We also observed enhanced activity of YES in TWEAK-treated glioma cells. Epidermal growth factor receptor vIII, the most frequent epidermal growth factor receptor mutation observed in GB (47) , promoted Src and Fyn activity, subsequently promoting GB cell motility (24) . The SFK inhibitor dasatinib inhibited invasion and induced apoptosis in vivo, suggesting that targeting SFK may be a viable therapeutic avenue for invading tumor cells. The targeting of specific SFKs in GB contexts may be necessary to affect cell invasion promoted by differing drivers.
Although the expression and activation of SFKs are known to be elevated in multiple tumor types, the contribution of individual SFKs to patient survival is understudied. Du et al. (19) demonstrated active Src in 61% of primary GB patients and showed by immunohistochemistry that active SFK was present in 22 of 31 primary GB specimens. In this work, we demonstrated that Lyn, but not Src, expression correlated with advanced tumor grade and shortened patient survival. The expression of Hck also correlated with advancing tumor grade, while Fyn was more highly expressed in lower grade brain tumors compared with NB or advanced tumor grade. Only Lyn and Yes significantly correlated with poor patient survival. Immunostaining previously showed that Lyn is primarily located in GB cells in tumor biopsies (21) . Thus, individual SFK members may prove to be better therapeutic targets for GB patients. To date, only pan-SFK inhibitors such as dasatinib have been used in clinical trials, with limited results (48). 
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In summary, the ability of TWEAK to act as a chemotactic factor for glioma tumor cells provides a unique mechanism of tumor cell infiltration into the brain. TWEAK-induced chemotactic migration in GB cells activates SFK members, specifically Lyn, leading to Rac1 activity ( Figure 6 ). Depletion of Lyn was sufficient to suppress TWEAK-induced chemotaxis and Rac1 activation. The expression of Lyn correlated with advanced brain tumor grade and shortened patient survival. Thus, the TWEAK/Fn14 signaling pathway through Lyn may be a vulnerable node for targeting invasive glioma cells. Supplementary Figures 1-3 
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